gemcitabine has been researched along with Electrolytes in 2 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 1 (50.00) | 29.6817 |
| 2010's | 0 (0.00) | 24.3611 |
| 2020's | 1 (50.00) | 2.80 |
| Authors | Studies |
|---|---|
| Benitez-Escobar, EN; Bonilla-Bonilla, DM; Daza-Arana, JE; Escobar-Dávila, SL; Galindes-Casanova, DA; Melo-Burbano, LÁ; Osorio-Toro, LM; Rivas-Tafurt, GP | 1 |
| Adjei, AA; Alberts, SR; Atherton, P; Bruzek, LM; Croghan, GA; Erlichman, C; Goldberg, RM; Hanson, LJ; Kaufmann, SH; Marks, RS; Palmer, PA; Pitot, HC; Reid, JM; Sloan, JA; Thibault, A | 1 |
1 trial(s) available for gemcitabine and Electrolytes
| Article | Year |
|---|---|
A Phase I trial of the farnesyl protein transferase inhibitor R115777 in combination with gemcitabine and cisplatin in patients with advanced cancer.
Topics: Adult; Aged; Alkyl and Aryl Transferases; Antineoplastic Combined Chemotherapy Protocols; Cisplatin; Deoxycytidine; Dose-Response Relationship, Drug; Electrolytes; Enzyme Inhibitors; Farnesyltranstransferase; Female; Gemcitabine; Humans; Immunohistochemistry; Male; Maximum Tolerated Dose; Middle Aged; Mouth Mucosa; Neoplasms; Quinolones; Time Factors | 2003 |
1 other study(ies) available for gemcitabine and Electrolytes
| Article | Year |
|---|---|
First case report of tumor lysis syndrome after third line systemic therapy with gemcitabine and pazopanib in a patient with lower extremity soft tissue sarcoma.
Topics: Electrolytes; Female; Gemcitabine; Humans; Sarcoma; Tumor Lysis Syndrome | 2023 |